SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hepatocellular Carcinoma: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hepatocellular Carcinoma.

Related Posts

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for ...

Oct 25, 2023

STAT+: Pharmalittle: Winners and losers from Medicare d...

Aug 31, 2023

Lutetium (lu177) lilotomab satetraxetan by Thor Medical...

Aug 28, 2023